ERBB2 and breast cancer: Indeed, a study from 2008 showed that HER2-induced mammary tumors in transgenic mice had significantly suppressed LRIG1 protein levels, and the activation of HER2 induced a further dramatic loss of endogenous LRIG1 expression and enhancement of proliferation via Akt/Erk, showing that HER2 oncogenic signaling actively contributes to suppression of LRIG [66].